Rossari Biotech Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rossari Biotech Limited generated cash of $432,550,000, which is less than the previous year. Cash used in financing activities reached the amount of $161,850,000 last year. Net change in cash is therefore -$440,280,000.
Cash Flow
| 2018 | 255.69M | -204.37M | -64.95M |
|---|---|---|---|
| 2020 | 548.28M | -1.90B | 1.56B |
| 2021 | 477.67M | -371.79M | -245.92M |
| 2023 | 1.52B | -1.80B | 608.55M |
| 2024 | 432.55M | -1.03B | 161.85M |
ROSSARI.NS Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | |
|---|---|---|---|---|---|
Cash at beginning of period | 691.98M | 374.77M | 292.11M | 57.42M | 21.35M |
Operating activities | |||||
Net income | 1.30B | 1.44B | 1.06B | 880.59M | 374.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 603.9M | 629.31M | 228.29M | 168.52M | 51.73M |
Stock-based compensation expense | 9.17M | 9.43M | 16.27M | 4.63M | 0 |
| Deferred income tax benefit | 9.17M | 9.43M | 16.27M | 4.63M | 0 |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | -1.12B | -279.69M | -404.5M | -204.06M | -110.86M |
Inventories | -938.48M | 7.32M | -320.25M | -37.65M | -101.2M |
Accounts payable | 496.34M | 400K | 241.7M | -68.97M | 110.85M |
Cash generated by operating activities | 432.55M | 1.52B | 477.67M | 548.28M | 255.69M |
Investing activities | |||||
Purchases Of Investments | 0 | -534.37M | -195.31M | -181.31M | -69.11M |
Investments In Property Plant And Equipment | -1.31B | -328.76M | -580.84M | -759.71M | -139.25M |
Acquisitions Net | -177.33M | -985.31M | -43.39M | -43.93M | 0 |
Cash generated by investing activities | -1.03B | -1.80B | -371.79M | -1.90B | -204.37M |
Financing activities | |||||
Common Stock Issued | 38.45M | 42.12M | 426.53M | 1B | 0 |
Payments for dividends | -27.58M | -27.53M | -25.38M | -26.48M | -2.65M |
Repurchases of common stock | 0 | 0 | -309.47M | 0 | 0 |
Repayments of term debt | 318.99M | 655.01M | -339.6M | 628.91M | -48.71M |
Cash used in financing activities | 161.85M | 608.55M | -245.92M | 1.56B | -64.95M |
Net Change In Cash | -440.28M | 323.55M | -140.03M | 234.69M | -15.1M |
Cash at end of period | 251.7M | 698.32M | 152.08M | 292.11M | 6.25M |
| Data source | Data source | Data source | Data source | Data source |